

Healthcare resource utilization and medical costs for children with interstitial lung diseases (chILD) in Europe

Elias Seidl¹, Nicolaus Schwerk², Julia Carlens², Martin Wetzke², Steve Cunningham³, Nagehan Emiralioğlu⁴, Nural Kiper⁴, Joanna Lange⁵, Katarzyna Krenke⁵, Nicola Ullmann⁶, Dora Krikovszky⁷, the chILD-EU collaborators, Phillen Maqhuzu^{8,9}, Charlotte A. Griese¹⁰, Larissa Schwarzkopf^{8,9,11*}, and Matthias Griese^{1,9*}

Online Data Supplement

Supp. Tab. 1a: German unit costs[21] updated for the base year (2015) – Outpatient care, inpatient care, medical aids, informal care, transportation, inpatient accompaniment, and average gross salary

	Unit costs (in €)	Units
Outpatient care		
General practitioner	21.41	Per contact
Children's doctor	36.93	Per contact
Internist	62.25	Per contact
Surgeon	45.88	Per contact
Orthopaedist	26.17	Per contact
Neurologist	48.31	Per contact
Dermatologist	20.38	Per contact
Ophthalmologist	40.56	Per contact
Urologist	25.38	Per contact
Gynaecologist	33.39	Per contact
Other Specialist	53.11	Per contact
Outpatient emergency care	126.00	Per contact
Psychologist	80.27	Per contact
Physiotherapist	18.23	Per contact
Speech and language therapist	42.33	Per contact
Occupational therapist	40.44	Per contact
Nutritionist	40.44	Per contact
Alternative medicine	53.11	Per contact
Outpatient rehabilitation	52.54	Per day
Outpatient nursing service	42.16	Per hour
Inpatient care		
Inpatient care/hospital	693.58	Per day
Inpatient care/Intensive care unit	1504.16	Per day
Inpatient rehabilitation	134.60	Per day
Medical aids	various	Per unit
Informal care	18.94	Per hour
Transportation	0.30	Per kilometer
Inpatient accompaniment	45.00	Per day
Average gross salary	17.59	Per hour

Supp. Tab. 1b: German unit costs for the base year (2015) – Medical aids

Medical aids	Unit costs (in €)
Oxygen concentrator	65.5
Oxygen tank	571.2
Liquid oxygen	714.0
Inhalation devicea	89.3
Non-invasive ventilation	603.1
Artificial respiration	912.5
Pulse oximeter	228.3
Breath/heart rate monitor	734.0
Peak flow meter	23.8
Flutter	69.0
Suction machine	139.0
Artificial feeding	505.9
Wheelchair	222.3
Nursing bed	407.3
Walking frame	111.0
Rehab-buggy	111.0

Supp. Tab. 2a: Distribution of included subjects in the study (n=445) in the chILD: disease categories and subcategories

Category	Subcategory	Number (percentage) of patients included in the study
A1 - DPLD-Diffuse developmental disorders		15 (3%)
	ACD without misalignment of pulmonary veins	2 (14%)
	ACD with misalignment of pulmonary veins (FOXF1 mutation)	5 (33%)
	Congenital alveolar dysplasia	1 (7%)
	TBX4 mutation	7 (46%)
A2 - DPLD-Growth abnormalities deficient alveolarization		29 (6%)
	Pulmonary hypoplasia	4 (14%)
	Pulmonary hypoplasia associated with diaphragmatic hernia	1 (3%)
	Pulmonary hypoplasia associated with oligohydramnion	1 (3%)
	Related to chromosomal disorders	9 (32%)
	Related to congenital heart disease	1 (3%)
	Related to preterm birth (BPD-cLDI)	10 (35%)
	Related to preterm birth (Wilson Mikity, new BPD)	1 (3%)
	No subcategory	2 (7%)
A3 - DPLD-Infant conditions of undefined aetiology		94 (21%)
	Persistent tachypnea of infancy (PTI)	76 (81%)
	Pulmonary interstitial glycogenosis (PIG)	11 (12%)
	No subcategory	7 (7%)
A4 - DPLD-related to alveolar surfactant region		99 (22%)
	ABCA3 mutation	26 (27%)
	Alveolar microlithiasis	3 (3%)
	Desquamative interstitial pneumonia	2 (2%)
	FARS-B mutation	1 (1%)
	Lipoidpneumonitis, Cholesterol pneumonia	1 (1%)
	Nkx21 gene defect	5 (5%)
	Nonspecific interstitial pneumonia (NSIP)	16 (16%)
	Pulmonary alveolar proteinosis	19 (19%)
	Pleuroparenchymal fibroelastosis	1 (1%)
	Surfactant protein B mutations	1 (1%)
	Surfactant protein C mutations	14 (14%)
	Usual interstitial pneumonitis	1 (1%)
	No subcategory	9 (9%)

Ax - DPLD-unclear RDS in the mature neonate		7 (2%)	
Ay - DPLD-unclear RDS in the almost mature neonate		7 (2%)	
B1 - DPLD-related to systemic disease processes		62 (14%)	
	Achondrodysplasia		1 (2%)
	Cantu syndrome		3 (5%)
	Congenital muscle disease		1 (2%)
	Diffuse alveolar hemorrhage due to vasculitic disorders		1 (2%)
	Eosinophilic granulomatosis with polyangiitis		4 (6%)
	Filamin A mutation		7 (11%)
	Granulomatosis with polyangiitis		8 (13%)
	Hermansky-Pudlak syndrome		1 (2%)
	Immune-mediated / collagen vascular disorders		4 (6%)
	Immunoglobulin G4-related disease		1 (2%)
	Lane-Hamilton syndrome		2 (3%)
	Langerhans cell histiocytosis		3 (5%)
	Loeys-Dietz syndrome		1 (2%)
	M. Osler		2 (3%)
	Microscopic polyangiitis		1 (2%)
	Pulmonary thrombotic microangiopathy due to atypical HUS		1 (2%)
	Sarcoidosis		7 (11%)
	Storage disease		4 (6%)
	Systemic lupus erythematosus		1 (2%)
	Undifferentiated connective tissue disease		2 (3%)
	No subcategory		7 (11%)
B2 - DPLD-in the presumed immune intact host related to exposures		56 (13%)	
	Bronchiolitis obliterans		16 (29%)
	Bronchiolitis obliterans organizing pneumonia		1 (2%)
	Bronchiolitis without transplantation		1 (2%)
	Diffuse alveolar damage and acute interstitial Pneumonia		1 (2%)
	Eosinophilic pneumonitis		1 (2%)
	Eosinophilic pneumonitis and bronchiolitis obliterans		1 (2%)
	Hypersensitivity pneumonitis		8 (14%)
	Infectious Bronchiolitis and postinfectious constructive bronchiolitis		5 (9%)

	Infectious / post-infectious processes	17 (30%)
	NSIP	2 (4%)
	Radiation lung injury	1 (2%)
	Toxic inhalation and bronchiolitis obliterans	1 (2%)
	No subcategory	1 (2%)
B3 - DPLD-in the immunocompromised host or transplanted		23 (5%)
	Bronchiolitis obliterans	3 (13%)
	COPA syndrome	3 (13%)
	Diffuse lung damage of unknown aetiology	1 (4%)
	Follicular bronchitis	1 (4%)
	Infections-miscellaneous	3 (13%)
	Infections-phagocyte defects	1 (4%)
	Infections-T cell deficiencies	1 (4%)
	Lymphocytic interstitial pneumonia	1 (4%)
	NSIP	2 (9%)
	Related to therapeutic intervention	1 (4%)
	Related to transplantation and rejection	2 (9%)
	Related to transplant, rejection and bronchiolitis obliterans	2 (9%)
	STING associated vasculopathy	2 (9%)
B4 - DPLD-related to lung vessels structural processes		35 (8%)
	Congestive changes related to cardiac dysfunction	1 (3%)
	Diffuse alveolar hemorrhage	1 (3%)
	Idiopathic pulmonary hemosiderosis	12 (34%)
	Lymphangiectasis	2 (6%)
	Pulmonary capillary hemangiomatosis	1 (3%)
	Pulmonary hemorrhage	6 (17%)
	Pulmonary hypertension	11 (31%)
	No subcategory	1 (3%)
B5 - DPLD-related to reactive lymphoid lesions		5 (1%)
	Follicular bronchitis	1 (20%)
	Lymphocytic interstitial pneumonia	3 (60%)
	Nodular lymphoid hyperplasia of the lung	1 (20%)
Bx - DPLD-unclear RDS in the NON-neonate		9 (2%)
By - DPLD-unclear NON-neonate		4 (1%)

Supp. Tab. 2b: Distribution of included subjects in the study (n=445) in the chILD: country the patient was treated in

Country the patient was treated in	Number (percentage) of patients included in the study
Germany	419 (54%)
Italy	28 (4%)
Poland	47 (6%)
Turkey	71 (9%)
UK	99 (13%)
other	110 (14%)

Supp. Tab. 2c: Distribution of included subjects in the chILD disease categories across different countries

	Germany	UK	Turkey	Poland	Italy	Other
A1 - DPLD-Diffuse developmental disorders	4%	1%	0%	0%	6%	5%
A2 - DPLD-Growth abnormalities deficient alveolarization	10%	10%	0%	6%	0%	0%
A3 - DPLD-Infant conditions of undefined aetiology	19%	21%	3%	57%	6%	14%
A4 - DPLD-related to alveolar surfactant region	19%	21%	48%	17%	25%	19%
Ax - DPLD-unclear RDS in the mature neonate	1%	3%	10%	0%	0%	0%
Ay - DPLD-unclear RDS in the almost mature neonate	2%	1%	3%	0%	0%	10%
B1 - DPLD-related to systemic disease processes	21%	6%	13%	9%	19%	10%
B2 - DPLD-in the presumed immune intact host related to exposures	7%	11%	7%	6%	44%	29%
B3 - DPLD-in the immunocompromised host or transplanted	7%	6%	0%	0%	0%	5%
B4 - DPLD-related to lung vessels structural processes	7%	11%	3%	6%	0%	5%
B5 - DPLD-related to reactive lymphoid lesions	2%	0%	3%	0%	0%	0%
Bx - DPLD-unclear RDS in the NON-neonate	1%	3%	10%	0%	0%	5%
By - DPLD-unclear NON-neonate	0%	4%	0%	0%	0%	0%

Supp. Tab. 2d: Distribution of 445 subjects in the chILD disease subcategories across different countries

	Germany	UK	Turkey	Poland	Italy	Other
ABCA3 mutations 1	0%	0%	4%	0%	0%	0%
ABCA3 mutations 2	6%	5%	8%	6%	0%	6%
ACD no MPV	1%	0%	0%	0%	0%	0%
ACD+MPV+FOXF1 mutation	1%	0%	0%	0%	0%	6%
Achondroplasia	1%	0%	0%	0%	0%	0%
ACD + MPV no FOXF1	0%	0%	0%	3%	0%	0%
Alveolar microlithiasis	0%	0%	12%	0%	0%	0%
BO	1%	0%	0%	0%	0%	0%
Bronchiolitis obliterans	1%	3%	0%	0%	29%	11%
Cantu Syndrome (Hypertrichosis, facial, Osteochond)	1%	0%	4%	0%	0%	0%
Lane-Hamilton-syndrome	1%	0%	0%	3%	0%	0%
Persistent tachypnea of infancy (PTI)	14%	17%	4%	59%	7%	11%
Chronic, completely unclear	0%	5%	0%	0%	0%	0%
Congenital alveolar dysplasia	0%	2%	0%	0%	0%	0%
Congenital muscle disease	1%	0%	0%	0%	0%	0%
Congestive changes related to cardiac dysfunction	1%	0%	0%	0%	0%	0%
COPA syndrome	1%	0%	0%	0%	0%	0%
Diffuse Alveolar Damage	0%	0%	0%	0%	0%	6%
Diffuse alveolar hemorrhage due to vasculitic diso	1%	0%	0%	0%	0%	0%
Diffuse lung damage of unknown aetiology	1%	0%	0%	0%	0%	0%
DIP	1%	0%	0%	0%	0%	0%
EGPA - Eosinophilic granulomatosis with polyangiitis	2%	2%	0%	0%	0%	0%
Eosinophilic pneumonitis	0%	2%	0%	0%	0%	0%
Exogen allergic alveolitis/hypersensitivity pneumonitis	3%	2%	4%	3%	0%	0%
FARSB mutation	0%	0%	4%	0%	0%	0%
Filamin A Mutation	2%	2%	4%	0%	0%	0%

Follicular bronchitis/bronchiolitis	1%	0%	0%	0%	0%	0%
GPA - Granulomatosis with polyangiitis (Wegener)	2%	2%	0%	3%	0%	6%
Hermansky-Pudlak Syndrome	1%	0%	0%	0%	0%	0%
Idiopathic pulmonary hemosiderosis (IPH)	1%	7%	0%	3%	0%	0%
Immune-mediated/collagen vascular disorders	1%	0%	0%	0%	0%	6%
Immunoglobulin G4-related disease (IgG4-RD)	1%	0%	0%	0%	0%	0%
Infections-Miscellaneous	1%	0%	0%	0%	0%	6%
Infections-Phagocyte defects	0%	2%	0%	0%	0%	0%
Infections-T cell deficiencies	1%	0%	0%	0%	0%	0%
Infectious Bronchiolitis and Postinfectious Constr	1%	2%	0%	0%	0%	0%
Infectious/post-infectious processes	2%	3%	4%	3%	21%	6%
Langerhans cell histiocytosis	1%	0%	0%	3%	0%	0%
LIP	0%	2%	0%	0%	0%	0%
Lipoidpneumonitis, Cholesterol pneumonia	0%	0%	0%	3%	0%	0%
Loeys-Dietz	1%	0%	0%	0%	0%	0%
Lymphangiectasis	0%	2%	0%	0%	0%	0%
Lymphocytic interstitial pneumonia (LIP)	1%	0%	4%	0%	0%	0%
M. Osler	1%	0%	0%	0%	0%	0%
Nkx21 gene defect	2%	0%	0%	3%	0%	0%
Nodular lymphoid hyperplasia of the lung	1%	0%	0%	0%	0%	0%
Nonspecific interstitial pneumonia (NSIP)	4%	10%	0%	0%	0%	6%
Pulmonary alveolar proteinosis	3%	3%	24%	3%	0%	0%
Pleuroparenchymal fibroelastosis	1%	0%	0%	0%	0%	0%
Pulmonary capillary hemangiomatosis	1%	0%	0%	0%	0%	0%
Pulmonary hemorrhage	1%	3%	0%	0%	0%	6%
Pulmonary hypertension	4%	0%	8%	3%	0%	6%
Pulmonary hypoplasia	1%	2%	0%	0%	0%	0%
Pulmonary hypoplasia associated with diaphragmatis	1%	0%	0%	0%	0%	0%

Pulmonary hypoplasia associated with oligohydramnis	0%	2%	0%	0%	0%	0%
Pulmonary interstitial glycogenosis (PIG)	6%	0%	0%	0%	0%	6%
Pulmonary thrombotic microangiopathy due to atypic	1%	0%	0%	0%	0%	0%
Radiation Lung Injury	1%	0%	0%	0%	0%	0%
Related to chromosomal disorders	3%	3%	0%	3%	0%	0%
Related to congenital heart disease	1%	0%	0%	0%	0%	0%
Related to preterm birth (BPD-cLDI)	4%	5%	0%	0%	0%	0%
Related to preterm birth (Wilson Mikity, new BPD)	1%	0%	0%	0%	0%	0%
Related to therapeutic intervention	0%	2%	0%	0%	0%	0%
Related to transplantation and rejection	1%	0%	0%	0%	0%	0%
Related to Tx or rejection+BO	1%	0%	0%	0%	0%	0%
Sarcoidosis	3%	2%	0%	0%	0%	0%
STING associated vasculopathy	0%	2%	0%	0%	0%	0%
Storage diseases	1%	0%	4%	0%	14%	0%
Surfactant protein C mutations	4%	7%	0%	0%	21%	6%
Systemic lupus erythematosus	1%	0%	0%	0%	0%	0%
TBX4 mutation	2%	0%	0%	0%	7%	0%
Toxic inhalation+BO	0%	0%	0%	0%	0%	6%
Unclear DPLD/ILD	1%	3%	12%	0%	0%	6%
Undifferentiated connective tissue disease	1%	0%	0%	0%	0%	0%

Supp. Tab. 3: Unadjusted mean (standard deviation; range) of costs (€) at baseline stratified by countries

	Germany 176	UK 70	Turkey 31	Poland 35
Direct medical costs	23,791 (38,109; 0 – 150,360)	14,124 (29,918; 0 – 142,277)	16,107 (32,374; 0 – 148,138)	25,493 (37,075; 0 – 136,793)
Outpatient medical care	427 (627; 0 – 4,069)	475 (794; 0 – 5,484)	117 (190; 0 – 759)	273 (434; 0 – 2,213)
Inpatient medical care	22,752 (37,969; 0 – 148,912)	12,431 (29,296; 0 – 135,374)	15,735 (32,327; 0 – 148,101)	24,709 (36,443; 0 – 135,374)
Rehabilitation	71 (6,27; 0 – 7,268)	-	-	296 (1,486; 0 – 8,749)
Use of medical aid	541 (638; 0 – 3,053)	558 (628; 0 – 3,500)	256 (353; 0 – 921)	215 (395; 0 – 1,468)
Direct non-medical costs	1,321 (3,134; 0 – 21,408)	1,150 (3,172; 0 – 23,184)	533 (955; 0 – 4,051)	1,332 (1,655; 0 – 7,227)
Professional care	-	660 (4,918; 0 – 41,148)	-	-
Informal care	728 (3,009; 0 – 20,455)	695 (3,092; 0 – 23,183)	-	23 (78; 0 – 336)
Transportation	88 (118; 0 – 720)	17 (28; 0 – 182)	180 (540; 0 – 2,160)	107 (138; 0 – 602)
Accompaniment in hospital	504 (957; 0 – 4,860)	438 (958; 0 – 4,095)	353 (840; 0 – 4,050)	1,202 (1,623; 0 – 6,975)
Indirect costs (productivity loss)	1,927 (4,371; 0 – 27,863)	1,705 (4,466; 0 – 30,958)	2,090 (3,681; 0 – 14,635)	1,974 (4,595; 0 – 17,871)
Total costs of illness	27,039 (40,263; 0 – 164,703)	16,978 (31,779; 0 – 153,785)	18,730 (35,261; 0 – 163,133)	28,799 (41,252; 0 – 140,975)

Supp. Tab. 3: Mean (standard deviation; range) of costs (€) at baseline stratified by countries (continued)

	Italy 16	Other 21
Direct medical costs	5,549 (14,101; 84 – 57,975)	12,392 (16,896; 0 – 50,659)
Outpatient medical care	246 (202; 0 – 745)	392 (785; 0 – 3,680)
Inpatient medical care	4,683 (14,190; 0 – 57,584)	11,366 (17,070; 0 – 50,548)
Rehabilitation	23 (94; 0 – 374)	266 (1,055; 0 – 4,846)
Use of medical aid	597 (686; 0 – 2,051)	362 (568; 0 – 1,946)
Direct non-medical costs	332 (640; 0 – 2,577)	531 (912; 0 – 2,805)
Professional care	-	6 (28; 0 – 126)
Informal care	39 (91; 0 – 288)	32 (101; 0 – 336)
Transportation	71 (113; 0 – 339)	68 (126; 0 – 536)
Accompaniment in hospital	222 (634; 0 – 2,565)	431 (836; 0 – 2,700)
Indirect costs (productivity loss)	2,832 (4,621; 0 – 15,479)	1,317 (2,439; 0 – 8,443)
Total costs of illness	8,713 (15,018; 207 – 60,552)	14,239 (18,364; 0 – 58,541)

Supp. Tab. 4: Unadjusted mean (standard deviation; range) of costs (€) at baseline stratified by diagnosis

	A1	A2	A3	A4
	10	27	74	78
Direct medical costs	39,663 (43,849; 332 – 136,211)	33,895 (48,407; 0 – 14,9515)	14,609 (26,024; 0 – 14,9580)	24,686 (42,555; 0 – 14,9556)
Outpatient medical care	219 (340; 0 – 912)	566 (1,039; 0 – 5,484)	378 (479; 0 – 3,257)	241 (450; 0 – 2,213)
Inpatient medical care	38,016 (43,144; 0 – 13,4564)	32,298 (47,712; 0 – 14,8912)	13,863 (26,104; 0 – 14,8912)	23,855 (42,492; 0 – 148,101)
Rehabilitation	727 (2,298; 0 – 7,268)	324 (1,684; 0 – 8,749)	28 (155; 0 – 1,211)	1 (6; 0 – 53)
Use of medical aid	701 (757; 0 – 1,647)	707 (573; 0 – 1,538)	342 (388; 0 – 1,611)	560 (658; 0 – 2,515)
Direct non-medical costs	1,602 (1,819; 0 – 5,353)	1,076 (1,686; 0 – 7,227)	843 (2,076; 0 – 17,046)	890 (1,771; 0 – 11,195)
Professional care	-	-	-	29 (231; 0 – 2,024)
Informal care	10 (30; 0 – 96)	179 (362; 0 – 1,818)	310 (1,982; 0 – 17,046)	330 (1,453; 0 – 10,909)
Transportation	139 (236; 0 – 650)	63 (84; 0 – 379)	68 (106; 0 – 602)	104 (346; 0 – 2,160)
Accompaniment in hospital	1,454 (1,737; 0 – 4,860)	833 (1,686; 0 – 6,975)	466 (778; 0 – 4,455)	456 (1,026; 0 – 4,050)
Indirect costs (productivity loss)	4,271 (6,180; 0 – 15,479)	2,374 (4,458; 0 – 17,520)	1,812 (4,583; 0 – 27,863)	1,762 (4,587; 0 – 30,958)
Total costs of illness	45,536 (50,477; 332 – 155,800)	37,345 (51,215; 66 – 154,743)	17,265 (27,368; 0 – 150,151)	27,338 (44,366; 0 – 164,703)

Supp. Tab. 4: Mean (standard deviation; range) of costs (€) at baseline stratified by diagnosis (continued)

	Ax	Ay
	7	7
Direct medical costs	17,112 (11,929; 1,712 – 32,631)	31,313 (23,713; 1,680 – 69,765)
Outpatient medical care	163 (270; 0 – 755)	151 (200; 0 – 583)
Inpatient medical care	16,391 (12,050; 0 – 31,579)	30,778 (23,936; 0 – 69,400)
Rehabilitation	-	-
Use of medical aid	486 (449; 0 – 957)	239 (334; 0 – 865)
Direct non-medical costs	3,725 (8,588; 12 – 23,184)	1,264 (1,263; 13 – 2,973)
Professional care	72 (191; 0 – 506)	145 (382; 0 – 1,012)
Informal care	3,408 (8,721; 0 – 23,183)	48 (127; 0 – 336)
Transportation	22 (27; 2 – 72)	53 (93; 0 – 259)
Accompaniment in hospital	296 (287; 0 – 630)	1,164 (1,257; 0 – 2,925)
Indirect costs (productivity loss)	1,277 (1,792; 0 – 4362)	2,804 (3,237; 0 – 9,147)
Total costs of illness	22,114 (10,030; 8,173 – 34,491)	35,381 (26,107; 3,781 – 81,885)

Supp. Tab. 4: Unadjusted mean (standard deviation; range) of costs (€) at baseline stratified by diagnosis (continued)

	B1 53	B2 37	B3 17	B4 24
Direct medical costs	13,359 (26,716; 0 – 137,663)	9,238 (17,921; 0 – 68,854)	26,498 (40,366; 74 – 150,360)	23,644 (39,790; 60 – 136,505)
Outpatient medical care	376 (397; 0 – 1,567)	458 (882; 0 – 4,069)	855 (944; 0 – 2,905)	490 (811; 0 – 3,528)
Inpatient medical care	12,607 (26,568; 0; 135,951)	8,340 (17,307; 0 – 62,890)	24,327 (40,234; 0 – 148,912)	22,635 (39,618; 0 – 135,374)
Rehabilitation	21 (108; 0 – 683)	128 (665; 0 – 4,038)	285 (1,175; 0 – 4,846)	-
Use of medical aid	337 (525; 0 – 1,712)	312 (532; 0 – 2,363)	1,016 (908; 0 – 3,053)	513 (785; 0 – 3,500)
Direct non-medical costs	882 (1,914; 0 – 9,437)	465 (954; 0 – 5,106)	1,689 (3,378; 0 – 14,275)	2,642 (5,337; 0 – 21,408)
Professional care	19 (139; 0 – 1,012)	-	15 (61; 0 – 253)	5 (26; 0 – 126)
Informal care	400 (1,742; 0 – 9,091)	45 (111; 0 – 336)	1,007 (3,376; 0 – 14,091)	1,800 (5,233; 0 – 20,455)
Transportation	85 (117; 0 – 473)	85 (153; 0 – 720)	87 (98; 0 – 321)	68 (83; 0 – 344)
Accompaniment in hospital	397 (846; 0 – 4,140)	334 (810; 0 – 4,050)	596 (848; 0 – 2,250)	774 (1,250; 0 – 4,095)
Indirect costs (productivity loss)	2,250 (4,625; 0 – 17,871)	820 (1,606; 0 – 7,036)	1,606 (2,126; 0 – 7,036)	2,829 (5,583; 0 – 25,330)
Total costs of illness	16,492 (30,662; 0 – 157,186)	10,522 (18,746; 0 – 75,367)	29,793 (40,270; 76 – 150,681)	29,115 (44,456; 89 – 153,785)

Supp. Tab. 4: Unadjusted mean (standard deviation; range) of costs (€) at baseline stratified by diagnosis (continued)

	B5 4	Bx 8	By 3
Direct medical costs	4,145 (4,199; 74 – 9,361)	4,666 (7,009; 0 – 19,549)	45,787 (47,323; 348 – 94,793)
Outpatient medical care	243 (300; 0 – 670)	267 (279; 0 – 759)	356 (220; 126 – 564)
Inpatient medical care	3,180 (4,314; 0 – 9,134)	3,888 (6,722; 0 – 17,925)	31,429 (53,836; 0 – 93,592)
Rehabilitation	-	-	-
Use of medical aid	723 (836; 0 – 1,516)	512 (367; 0 – 942)	286 (323; 0 – 637)
Direct non-medical costs	4,637 (8,517; 0 – 17,406)	300 (319; 0 – 783)	1,224 (1,791; 50 – 3,285)
Professional care	-	-	13,716 (23,757; 0 – 41,148)
Informal care	4,262 (8,523; 0 – 17,046)	84 (156; 0 – 336)	112 (194; 0 – 336)
Transportation	195 (215; 0 – 498)	25 (39; 0 – 108)	2 (3; 0 – 5)
Accompaniment in hospital	180 (255; 0 – 540)	191 (305; 0 – 675)	1,110 (1,884; 0 – 3,285)
Indirect costs (productivity loss)	844 (1,689; 0 – 3,377)	1,293 (2,593; 0 – 7,036)	-
Total costs of illness	9,626 (11,968; 572 – 26,412)	6,259 (8,481; 0 – 20,284)	47,011 (48,870; 684 – 98,078)